Chromadex Corporation (CDXC): Modelo de Negócios Canvas [Jan-2025 Atualizado]

A Chromadex Corporation (CDXC) fica na vanguarda da inovação da saúde celular, transformando pesquisas científicas de ponta em soluções nutracêuticas inovadoras que prometem redefinir bem-estar e longevidade. Ao alavancar sua tecnologia proprietária de ribosídeo de nicotinamida (NR) e um portfólio de propriedade intelectual robusta, a empresa esculpiu um nicho único no mercado de suplementos de saúde em rápida evolução, oferecendo ingredientes cientificamente validados que direcionam mecanismos de metabolismo celular e antienvelhecimento. Mergulhe no intrincado modelo de negócios que alimenta essa empresa pioneira, revelando como o Chromadex está estrategicamente se posicionando para revolucionar a interseção da pesquisa científica e do bem -estar do consumidor.

Chromadex Corporation (CDXC) - Modelo de negócios: Parcerias -chave

Fabricantes de suplementos nutracêuticos e dietéticos

A Chromadex faz parceria com vários fabricantes nutracêuticos para produzir e distribuir produtos de NR (ribosídeo de nicotinamida):

Parceiro	Detalhes da colaboração	Linha de produtos
Pesquisa Thorne	Contrato de fabricação exclusivo	Base NAD+ Suplemento
Extensão da vida	Contrato de fornecimento de ingredientes	Suplementos de saúde baseados em NR

Instituições de pesquisa e universidades

Chromadex colabora com os principais centros de pesquisa acadêmica:

• Escola de Medicina de Harvard
• Universidade do Colorado
• Universidade de Cornell

Financiamento de pesquisa em 2023: US $ 2,3 milhões para estudos de metabolismo NAD+

Organizações de fabricação contratadas

As principais parcerias de fabricação incluem:

CMO	Capacidade de fabricação	Volume anual de produção
Pathon Pharmaceuticals	500 kg nr/mês	6.000 kg/ano
Soluções farmacêuticas catalentas	250 kg nr/mês	3.000 kg/ano

Empresas farmacêuticas e de biotecnologia

Parcerias estratégicas em desenvolvimento farmacêutico:

• Merck KGAA - Colaboração de pesquisa
• NESTEC S.A. - Desenvolvimento de ingredientes

Investimento de P&D em programas de parceria: US $ 4,7 milhões em 2023

Distribuidores de produtos para saúde e bem -estar

A rede de distribuição inclui:

Distribuidor	Alcance do mercado	Volume anual de vendas
Vitamin Shoppe	Estados Unidos	US $ 3,2 milhões
iherb	Plataforma on -line global	US $ 2,8 milhões

Chromadex Corporation (CDXC) - Modelo de negócios: Atividades -chave

Nicotinamida Ribosídeo (NR) Pesquisa e Desenvolvimento de Ingredientes

A Chromadex investiu US $ 5,7 milhões em despesas de pesquisa e desenvolvimento no terceiro trimestre de 2023. A empresa mantém uma equipe de pesquisa dedicada focada na inovação de ingredientes da NR.

Área de foco de pesquisa	Valor do investimento
NR Pesquisa molecular	US $ 2,3 milhões anualmente
Estudos de Metabolismo NAD+	US $ 1,5 milhão anualmente

Produção e comercialização patenteadas de NR

Chromadex detém várias patentes relacionadas à produção de NR, com 7 Patentes -chave que protegem seu processo de fabricação proprietária.

• Marca registrada: ingrediente Niagen®
• Capacidades exclusivas de fabricação comercial da NR
• Capacidade de produção: 250 kg de NR por mês

Formulação de suplementos alimentares

Produto de suplemento	Receita anual
Suplementos TRUNIAGEN®	US $ 42,6 milhões em 2022
Vendas de ingredientes para parceiros	US $ 18,3 milhões em 2022

Pesquisa científica e ensaios clínicos

O Chromadex apoiou 12 ensaios clínicos concluídos Investigar os potenciais benefícios à saúde da NR.

• Colaborações com 8 principais universidades de pesquisa
• Mais de 30 publicações científicas revisadas por pares
• Ensaios clínicos em andamento em saúde metabólica e envelhecimento

Gerenciamento de propriedade intelectual

A partir de 2023, o Chromadex mantém um portfólio robusto de propriedade intelectual.

Categoria IP	Número de ativos
Patentes ativas	23 patentes globais
Aplicações de patentes	15 Aplicações pendentes

Chromadex Corporation (CDXC) - Modelo de negócios: Recursos -chave

Tecnologias proprietárias de NMN e NR Ingredientes

Chromadex se mantém 5 patentes principais Relacionado às tecnologias de ingredientes NMN e NR. O portfólio de patentes de ribosídeo de nicotinamida (NR) inclui 8 patentes emitidas nos Estados Unidos.

Tecnologia	Status de patente	Duração da proteção
Ingrediente NMN	5 patentes principais	Até 2035-2040
Ingrediente nr	8 emitiram patentes nos EUA	Até 2032-2037

Portfólio de propriedade intelectual

Chromadex mantém uma estratégia de propriedade intelectual abrangente com:

• 13 Patentes totais que cobrem tecnologias NR e NMN
• Proteção de patentes em múltiplas jurisdições, incluindo nós, Europa, Japão
• Processo de aplicação de patente em andamento para tecnologias emergentes

Capacidades de pesquisa científica

Métrica de pesquisa	2024 dados
Colaborações de pesquisa ativa	12 instituições acadêmicas
Ensaios clínicos em andamento	7 ensaios ativos
Publicou artigos científicos	38 Publicações revisadas por pares

Instalações de fabricação avançadas

Chromadex opera 2 instalações de fabricação registradas pela FDA com capacidade total de produção de 500 kg por mês para ingredientes NR e NMN.

Equipe científica e de pesquisa especializada

Composição da equipe	Número
Pesquisadores de doutorado	17
Cientistas de pesquisa	24
Pessoal de pesquisa total	41

Chromadex Corporation (CDXC) - Modelo de negócios: proposições de valor

Ingredientes precursores NAD+ de alta qualidade

Chromadex produz Ribosídeo de nicotinamida (NR) sob o ingrediente da marca Niagen. A partir do quarto trimestre de 2023, as vendas de ingredientes da Niagen foram de US $ 7,2 milhões, representando um fluxo de receita importante para a empresa.

Ingrediente	Produção anual	Valor de mercado
Niagen nr	Mais de 500 kg/ano	US $ 28,6 milhões (2023)

Suplementos de saúde e longevidade validados e validados

O Chromadex investiu em vários estudos clínicos que validam a eficácia do precursor NAD+.

• 7 ensaios clínicos humanos publicados
• Mais de US $ 10 milhões investidos em pesquisa e desenvolvimento
• Parcerias com 6 principais universidades de pesquisa

Soluções inovadoras de saúde celular

Linha de produtos	Mercado -alvo	Receita anual
Base	Saúde celular	US $ 12,4 milhões (2023)
Chromadex direto	Suplementos de consumo	US $ 5,6 milhões (2023)

Suporte de desempenho antienvelhecimento e metabólico

A Chromadex tem como alvo o mercado de bem -estar premium com produtos cientificamente formulados.

• Preço médio do produto Ponto: US $ 45 a US $ 75 por mês
• Demografia-alvo: 35-65 faixa etária
• Alcance do mercado global em 40 países

Ingredientes nutracêuticos premium para mercado de bem -estar

Categoria de ingredientes	Segmento de mercado	Crescimento projetado
NAD+ precursores	Saúde celular	15,6% CAGR (2023-2028)
Suporte metabólico	Nutracêuticos	12,3% CAGR (2023-2028)

Chromadex Corporation (CDXC) - Modelo de Negócios: Relacionamentos do Cliente

Vendas diretas para suplementar fabricantes

O Chromadex gera receita através de vendas diretas de NR (ribosídeo de nicotinamida) e outros produtos de ingredientes para fabricantes de suplementos alimentares.

Canal de vendas	Segmento de clientes	Volume anual de vendas
Vendas diretas de B2B	Fabricantes de suplementos alimentares	US $ 15,2 milhões (relatório de 2023 Q3)
Distribuição de ingredientes	Empresas nutracêuticas	US $ 8,7 milhões (relatório de 2023 Q3)

Plataformas de suporte ao cliente online

O Chromadex mantém o envolvimento digital do cliente por meio de várias plataformas on -line.

• E -mail de suporte técnico: support@chromadex.com
• Linha telefônica de atendimento ao cliente: +1 (949) 725-4700
• Formulário de consulta técnica do site
• Engajamento de rede profissional do LinkedIn

Conferência científica e engajamento de eventos da indústria

O Chromadex participa ativamente de conferências científicas para manter o relacionamento com os clientes.

Tipo de evento	Participação anual	Alcance de rede
Conferências científicas	7-9 eventos anualmente	Aproximadamente 500-750 profissionais do setor
Feiras nutracêuticas	4-6 eventos anualmente	Aproximadamente 300-450 clientes em potencial

Serviços de consulta de produto técnico

O Chromadex fornece consulta técnica especializada para desenvolvimento e integração de produtos.

• Consulta inicial gratuita para clientes em potencial
• Orientação de formulação personalizada
• Advogado de conformidade regulatória
• Apoio à interpretação da pesquisa científica

Parcerias de colaboração de pesquisa

O Chromadex estabelece parcerias de pesquisa estratégica para aprimorar o relacionamento com os clientes.

Tipo de parceria	Número de colaborações ativas	Investimento em pesquisa
Parcerias de pesquisa acadêmica	12 colaborações ativas	Suporte anual de pesquisa anual de US $ 1,2 milhão
Alianças de pesquisa corporativa	5 parcerias ativas	Financiamento anual de pesquisa colaborativa de US $ 750.000

Chromadex Corporation (CDXC) - Modelo de Negócios: Canais

Equipe de vendas diretas

O Chromadex mantém uma equipe de vendas direta especializada focada nos mercados nutracêuticos e científicos. A partir de 2023, a Companhia relatou 27 representantes de vendas diretas direcionando segmentos de mercado específicos.

Tipo de canal de vendas	Número de representantes	Mercado -alvo
Vendas diretas nutracêuticas	17	Varejistas de suplementos de saúde
Vendas de pesquisa científica	10	Instituições de pesquisa

Plataformas de comércio eletrônico

O Chromadex utiliza vários canais de vendas digitais com US $ 4,2 milhões em receita direta de vendas on -line em 2023.

• Site oficial da empresa
• Amazon Marketplace
• Loja online direta

Redes de distribuidores nutracêuticos

A empresa estabeleceu parcerias com 42 distribuidores nutracêuticos nacionais e internacionais.

Tipo de distribuidor	Número de parceiros	Alcance geográfico
Distribuidores norte -americanos	22	Estados Unidos e Canadá
Distribuidores internacionais	20	Europa, Ásia, Austrália

Apresentações da conferência científica

O Chromadex participou de 18 conferências científicas em 2023, apresentando pesquisas sobre NR (ribosídeo de nicotinamida) e compostos relacionados.

Marketing digital e presença na web

As despesas de marketing digital em 2023 foram de US $ 1,3 milhão, com as seguintes métricas de engajamento digital:

• Tráfego do site: 375.000 visitantes mensais exclusivos
• Seguidores de mídia social: 87.000 em plataformas
• Base de assinantes de e -mail: 45.000 assinantes

Chromadex Corporation (CDXC) - Modelo de negócios: segmentos de clientes

Fabricantes de suplementos alimentares

A Chromadex serve fabricantes de suplementos alimentares por meio de seu NR (Nicotinamida Riboside) Suppliente de ingredientes:

Segmento de mercado	Volume de compra anual	Valor médio do contrato
Fabricantes de Nível 1	US $ 3,2 milhões	$750,000
Fabricantes de Nível 2	US $ 1,8 milhão	$350,000

Bem-estar e mercados antienvelhecimento

Chromadex tem como alvo segmentos de bem -estar com ofertas específicas de produtos:

• Tamanho global do mercado antienvelhecimento: US $ 58,5 bilhões em 2023
• Penetração do mercado de Chromadex: 0,035%
• Faixa de idade do consumidor-alvo: 35-65 anos

Instituições de pesquisa nutricional

Detalhes do segmento de clientes da instituição de pesquisa:

Tipo de instituição	Contratos de pesquisa anuais	Valor médio do contrato
Centros de Pesquisa Universitária	12 contratos	$275,000
Laboratórios de pesquisa independentes	8 contratos	$185,000

Consumidores preocupados com a saúde

Análise do segmento do consumidor:

• Gastos demográficos alvo: US $ 487 por pessoa
• Taxa de conversão: 0,02%
• Locais primários de consumidores: Estados Unidos, Canadá, Europa Ocidental

Empresas de biotecnologia e farmacêutica

Engajamento farmacêutico do cliente:

Tipo de empresa	Número de parcerias ativas	Valor anual de colaboração
Grandes empresas farmacêuticas	3 parcerias	US $ 4,5 milhões
Empresas de biotecnologia	7 parcerias	US $ 2,3 milhões

Chromadex Corporation (CDXC) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2022, o Chromadex relatou despesas de pesquisa e desenvolvimento de US $ 12,1 milhões. Os gastos em P&D da empresa em 2021 foram de US $ 11,3 milhões.

Ano	Despesas de P&D
2021	US $ 11,3 milhões
2022	US $ 12,1 milhões

Custos de fabricação e produção

O custo de mercadorias da Chromadex vendido (COGS) para 2022 foi de US $ 23,4 milhões, em comparação com US $ 20,7 milhões em 2021.

Ano	Custo de mercadorias vendidas
2021	US $ 20,7 milhões
2022	US $ 23,4 milhões

Proteção à propriedade intelectual

A empresa investiu US $ 1,2 milhão em despesas legais e relacionadas a patentes em 2022.

• Custos de arquivamento de patentes
• Taxas de consulta legal
• Despesas de manutenção de IP

Operações de marketing e vendas

As despesas de marketing e vendas da Chromadex em 2022 totalizaram US $ 19,6 milhões, um aumento de US $ 17,2 milhões em 2021.

Ano	Despesas de marketing e vendas
2021	US $ 17,2 milhões
2022	US $ 19,6 milhões

Investimentos de conformidade regulatória

Chromadex alocado aproximadamente US $ 2,5 milhões para conformidade regulatória e garantia de qualidade em 2022.

• Custos de conformidade da FDA
• Investimentos de controle de qualidade
• Despesas de documentação regulatória

Chromadex Corporation (CDXC) - Modelo de negócios: fluxos de receita

Vendas de ingredientes para suplementar fabricantes

O Chromadex gera receita através das vendas de ingredientes de NR (ribosídeo de nicotinamida) para complementar os fabricantes. No ano fiscal de 2022, as vendas de ingredientes totalizaram US $ 11,1 milhões.

Produto	Receita anual (2022)
NR Vendas de ingredientes	US $ 11,1 milhões
Crescimento de vendas de ingredientes	15,7% ano a ano

Renda de royalties do licenciamento de tecnologia

O Chromadex ganha renda de royalties de acordos de licenciamento de tecnologia. Em 2022, a renda de royalties atingiu US $ 3,2 milhões.

Categoria de licenciamento	Renda anual de royalties (2022)
Licenciamento de tecnologia	US $ 3,2 milhões

Vendas diretas de produtos de consumo

A Chromadex vende produtos diretos ao consumidor por meio de sua marca Tru Niagen. No ano fiscal de 2022, as vendas diretas de produtos de consumo foram de aproximadamente US $ 24,5 milhões.

Linha de produtos	Vendas anuais (2022)
Vendas de consumidores Tru Niagen	US $ 24,5 milhões

Acordos de colaboração de pesquisa

O Chromadex gera receita por meio de acordos de colaboração de pesquisa com instituições acadêmicas e farmacêuticas.

• Receita total de colaboração de pesquisa em 2022: US $ 1,8 milhão
• Número de parcerias de pesquisa ativa: 12

Monetização da propriedade intelectual

A Chromadex monetiza seu extenso portfólio de propriedade intelectual por meio de várias estratégias de licenciamento e parceria.

Categoria de monetização IP	Receita anual (2022)
Licenciamento de patentes	US $ 0,9 milhão

Repartição total da receita para 2022:

Fluxo de receita	Quantia	Percentagem
Vendas de ingredientes	US $ 11,1 milhões	31.7%
Vendas diretas do consumidor	US $ 24,5 milhões	70.0%
Renda de royalties	US $ 3,2 milhões	9.1%
Colaborações de pesquisa	US $ 1,8 milhão	5.1%
Monetização IP	US $ 0,9 milhão	2.6%

ChromaDex Corporation (CDXC) - Canvas Business Model: Value Propositions

You're looking at the core reasons why customers choose ChromaDex Corporation (CDXC) over alternatives in the competitive NAD+ space. It's not just about a product; it's about the science backing it up, which translates directly into trust and perceived efficacy.

The primary value proposition is centered on Niagen, the patented ingredient, which is clinically proven to safely increase Nicotinamide Adenine Dinucleotide (NAD+) levels in humans. This is the foundation of everything ChromaDex Corporation (CDXC) offers.

The scientific backing is extensive, positioning the ingredient as the gold standard in scientific rigor, safety, and quality for NAD+ boosters. This isn't just marketing fluff; it's supported by a significant body of independent work.

• Supplementation with Niagen® is backed by over 20 published and peer-reviewed clinical trials.
• Over 65% of registered nicotinamide riboside trials utilize Niagen.
• ChromaDex Corporation (CDXC) maintains over 40 owned and licensed patents protecting its core technology.
• Over 90% of Niagen studies are third-party funded and investigator-initiated, showing independent validation.

For the everyday consumer, the value is delivered through the consumer-friendly dietary supplement, Tru Niagen, for healthy aging. The numbers here show significant traction in the direct-to-consumer market.

Here's the quick math on the consumer side, based on the latest full-year and recent quarterly results:

Metric	Value/Period	Source Year/Period
Tru Niagen Sales	$76.8 million	Full Year 2024
Tru Niagen Sales	$22.7 million	Fourth Quarter 2024 (Up 29% YoY)
Tru Niagen Sales	$26.0 million	Third Quarter 2025 (Up 44% YoY)
Market Position	Number one healthy-aging NAD+ supplement in the United States	As of early 2025

What this estimate hides is the ongoing investment required to maintain that number one spot, but the growth trajectory is clear. Also, ChromaDex Corporation (CDXC) projects approximately 18% year-over-year revenue growth for the full year 2025.

A major strategic expansion is the offering of pharmaceutical-grade Niagen IV and injections for clinical settings under the Niagen+ line. This moves the ingredient into a higher-margin, prescription-based channel.

The growth in the ingredient business, which includes pharmaceutical-grade sales, has been explosive. For instance, total Niagen® ingredient sales surged 368% to $6.7 million in the third quarter of 2024. This segment is clearly gaining momentum.

• The Niagen+ product line, featuring pharmaceutical-grade Niagen®, was available in over 475 U.S. wellness clinics by the end of 2024.
• By May 2025, the network offering Niagen® IV expanded to almost 600 clinics nationwide.
• The global intravenous hydration therapy market was valued at $2.32 billion globally in 2022, providing a large addressable market for the IV product.

Finally, the value proposition of transparency and trust built on published, peer-reviewed human trials is critical for a science-based company. This builds the moat around the product.

The latest data shows over 35 peer-reviewed clinical studies supporting Niagen. For example, a peer-reviewed study published in July 2024 demonstrated that a single 900 milligram dose of NR (Tru Niagen) increased brain NAD+ levels by about 16% within four hours in healthy adults. That's a concrete, measurable benefit you can point to.

Finance: draft 13-week cash view by Friday.

ChromaDex Corporation (CDXC) - Canvas Business Model: Customer Relationships

You're looking at how Niagen Bioscience, Inc. (formerly ChromaDex Corporation) interacts with its distinct customer groups as of late 2025. It's a multi-pronged approach, balancing high-volume consumer sales with specialized B2B and clinical channels. Honestly, the relationship management shifts significantly depending on who you're talking to.

Automated direct-to-consumer (DTC) subscription model via TruNiagen.com

The core consumer relationship is built on automation and convenience through the TruNiagen.com platform. This is where the bulk of the consumer revenue flows. For the third quarter of 2025, the Tru Niagen revenue grew by a strong 44% year-over-year, hitting $26 million. Within that, the e-commerce revenue alone was $19 million, showing a 29% or $4.3 million increase over the prior year's third quarter. Tru Niagen is positioned as the number one healthy-aging NAD+ supplement in the United States. The goal here is retention through a seamless, automated subscription experience, making sure the customer gets their supply without friction.

Dedicated account management for large B2B ingredient partners

For ingredient partners, the relationship is much more hands-on, involving dedicated account management to handle large-volume supply of Niagen®. This segment supports other manufacturers using the ingredient. In the third quarter of 2025, Niagen ingredient revenue reached $6.9 million, marking a 4% year-over-year increase. This total included $6.4 million in food-grade Niagen sales to key partners. To give you context from the prior full year, ingredient sales reached $19.2 million for all of 2024, which was up 82% from 2023.

Here's a quick look at how the revenue streams break down based on the latest reported quarter:

Customer Relationship Channel	Q3 2025 Revenue Amount	Year-over-Year Growth (Q3 2025)
DTC/E-commerce (Tru Niagen®)	$26 million	44%
B2B Ingredient Sales (Food-Grade)	$6.4 million	Implied within 4% total ingredient growth
Clinical Channel (Pharma-Grade)	$0.5 million	Implied within 4% total ingredient growth

Prescription-based relationship with U.S. wellness clinics

The clinical channel establishes a prescription-based relationship, primarily through the pharmaceutical-grade Niagen IV and injection offerings, which are distributed via U.S. FDA-registered 503B outsourcing facilities. This segment is growing rapidly. As of the announcement in September 2024, Niagen IV and injections were rolling out to 14 new clinics. By March 2025, the Niagen IV product was available in 500 clinics across the country, with management projecting that number to double by the end of 2025. As of the start of 2025, Niagen Plus products were already available at over 475 leading wellness clinics in the U.S.. This channel requires a high degree of trust and regulatory alignment with the clinics themselves.

High-touch scientific communication with researchers and media

The scientific communication strategy is high-touch because the product's value proposition rests entirely on rigorous science. This relationship management targets credibility building with key opinion leaders, researchers, and the media. The company continues to invest in research and innovation, supporting its claims. The communications engine is designed to amplify awareness of Niagen's 40 peer-reviewed published clinical studies. This scientific backing is critical for maintaining the premium positioning of Niagen as the most efficient, effective, and only legal NAD booster available.

The key touchpoints for this relationship focus include:

• Supporting ongoing research and development projects.
• Amplifying results from new clinical studies.
• Educating healthcare practitioners and consumers on NAD+ science.
• Maintaining transparency regarding safety and quality standards.

Finance: review Q3 2025 marketing spend allocation across DTC vs. clinical channel support by next Tuesday.

ChromaDex Corporation (CDXC) - Canvas Business Model: Channels

You're looking at how ChromaDex Corporation, which officially became Niagen Bioscience, Inc. (NAGE) in March 2025, gets its products to the customer. The channel strategy is clearly multi-pronged, balancing high-margin direct sales with broad market reach via established partners.

Direct-to-Consumer (DTC) e-commerce via TruNiagen.com remains a core focus, driving significant revenue. For the fourth quarter of 2024, this channel saw net sales of $17.3 million, representing robust organic growth of 30% year-over-year. This channel is expected to see continued expansion throughout 2025, supporting the overall projection of approximately 18% year-over-year revenue growth for the full fiscal year 2025. This DTC focus helps capture higher margins directly from the consumer base.

The company maintains a solid foothold in major online marketplaces. While Amazon is noted as historically doing the heavy lifting, the Shopify platform is reportedly starting to pull its weight after an initial underwhelming stretch. The overall e-commerce business, which includes these marketplaces, saw stable sales of $13 million in the second quarter of 2024. The overall strategy anticipates growth through these established partnerships.

International retail distribution is heavily reliant on key partners. The relationship with A.S. Watson Group, which includes Watsons, is a key component of the B2B segment. In the fourth quarter of 2024, combined sales through Watsons and other B2B channels increased by 26% compared to the prior year period. The partnership with iHerb is also critical for global reach, as nearly 90% of iHerb's sales are generated outside the United States, and iHerb serves 10 million active customers across more than 180 countries.

The newer channel involves U.S. wellness clinics and compounding pharmacies for the pharmaceutical-grade Niagen Plus products (IV/injections). This segment is showing rapid adoption. As of May 2025, pharmaceutical-grade Niagen IV was available in almost 600 clinics nationwide. Management expressed an expectation that this number would double by the end of 2025, suggesting this segment is targeted to become a steady source of revenue. This channel also includes the ingredient business, where food-grade and pharmaceutical-grade Niagen ingredient sales reached $5.3 million in Q4 2024, marking a 96% year-over-year increase for that quarter.

Here's a quick look at the performance metrics across the primary sales avenues based on the latest available figures:

Channel Type	Specific Channel/Metric	Latest Reported Value (Q4 2024 or Goal)	Context/Growth
Direct-to-Consumer (DTC)	TruNiagen.com Net Sales (Q4 2024)	$17.3 million	Up 30% year-over-year
Online Marketplaces	E-commerce Sales (Q2 2024)	$13 million	Reported as stable
International Retail	Watsons & Other B2B Sales (Q4 2024)	Combined Sales Increase	Up 26% year-over-year
Clinical/Prescription	Niagen IV Clinics (May 2025)	Almost 600 clinics	Goal to double by end of 2025
Ingredient Sales	Food/Pharma Grade Niagen Sales (Q4 2024)	$5.3 million	Up 96% year-over-year

The company's overall strategy relies on these distinct pathways to market:

• TruNiagen.com for direct customer relationship and margin capture.
• Amazon, iHerb, Walmart.com for broad online accessibility.
• Watsons and other partners for established international retail presence.
• Wellness Clinics for prescription-based, high-value IV/injection delivery.

The full-year 2024 net sales for ChromaDex Corporation reached $99.6 million, and the projection for 2025 is approximately 18% revenue growth, which depends on the successful execution across all these channels.

Finance: draft 13-week cash view by Friday.

ChromaDex Corporation (CDXC) - Canvas Business Model: Customer Segments

You're looking at the core groups ChromaDex Corporation (now Niagen Bioscience, Inc. as of March 19, 2025) serves to drive its revenue and research pipeline. This isn't just about selling a bottle; it's about supplying a science-backed ingredient across multiple channels.

The customer base is segmented into four distinct, yet interconnected, groups that rely on the company's flagship ingredient, Niagen (patented nicotinamide riboside or NR).

Health-conscious consumers focused on longevity and cellular health.

This segment buys the direct-to-consumer product, Tru Niagen®. This group is targeted as people focused on healthy aging and cellular health, seeking to boost NAD+ levels.

• Tru Niagen® is the number one healthy-aging NAD+ supplement in the United States, based on revenue per the largest U.S. e-commerce marketplace (as of the period ending February 29, 2024).
• For the full year 2024, net sales from Tru Niagen® reached $76.8 million.
• In the fourth quarter of 2024, Tru Niagen® net sales were $22.7 million.

B2B dietary supplement and functional food manufacturers.

These are other companies that purchase pharmaceutical-grade Niagen® as an active ingredient for their own branded products, including supplements and functional foods. This is a key ingredient licensing/supply stream.

Metric	2024 Full Year Amount	Q4 2024 Amount
Niagen Ingredients Net Sales	$19.2 million	Not explicitly stated separately from total Q4 ingredient sales, but Q3 2024 ingredient sales were $6.7 million.
Ingredient Sales YoY Growth (2024 vs 2023)	82%	Ingredient sales grew 368% year-over-year in Q3 2024.
B2B Sales as % of Net Sales (Historical Context)	Not specified for 2024	24% in Q1 2022.

The company also supplies pharmaceutical-grade Niagen® to U.S. FDA-registered 503B outsourcing facilities for compounding into injectable/IV products for clinics.

U.S. wellness and anti-aging clinics (over 475 clinics in 2024).

This segment purchases the Niagen Plus product line, which includes Niagen IV and injectables, available exclusively by prescription at participating clinics.

• As of the fiscal year 2024 results announcement (early 2025), Niagen Plus products were available at over 475 leading wellness clinics in the U.S..
• One analysis noted availability in 500 clinics across the country, with management expecting that number to double by the end of 2025.
• This availability was noted to have expanded to over 100 wellness clinics as of October 31, 2024.

Academic and pharmaceutical researchers.

This group engages with ChromaDex Corporation through the ChromaDex External Research Program (CERP™) to advance the science of NAD+.

Here's a look at the scale of the research engagement:

Research Metric	Number/Amount
Research Agreements Worldwide	275+
Countries with Research Agreements	30+
Peer-Reviewed Publications through CERP	200+
Published Human Clinical Studies	35+
Research Materials Provided (Cumulative)	Over $4.5 million

The company is also actively pursuing a pharmaceutical path, having initiated discussions with the FDA regarding an Investigational New Drug (IND) application for nicotinamide riboside (NR) in the treatment of Ataxia Telangiectasia (AT).

ChromaDex Corporation (CDXC) - Canvas Business Model: Cost Structure

You're looking at the expense side of Niagen Bioscience Inc.'s (formerly ChromaDex Corporation) operations as of late 2025. This structure shows where the money is going to support the science, brand, and supply chain for Niagen.

The cost structure is heavily weighted toward commercialization and maintaining scientific leadership. For the third quarter of 2025, total operating expenses increased 21%, or $3.1 million, to $17.7 million, reflecting investments for business growth and brand awareness.

Here is a breakdown of the key cost components for the third quarter of 2025:

• High R&D investment, totaling $1.8 million in Q3 2025.
• Significant selling and marketing expenses for brand expansion.
• General and administrative (G&A) expenses, $7.1 million in Q3 2025.
• Manufacturing and supply chain costs for Niagen production.
• Legal costs for patent defense and enforcement.

The primary operating expenses for the third quarter of 2025 are detailed below. Note that the company's net sales for the period were $34.0 million.

Cost Component	Q3 2025 Amount/Metric	Context/Detail
Research & Development (R&D)	$1.8 million	Expense was $0.5 million higher year-over-year, supporting science as the cornerstone of the company.
General & Administrative (G&A)	$7.1 million	This figure is as reported, though the full-year outlook was updated to expect G&A to be between $8.0 to $9.0 million.
Selling & Marketing (S&M)	25.8% of Net Sales	This percentage of net sales represents an improvement of 170 basis points year-over-year, despite an absolute dollar increase of $1.7 million year-over-year to support brand growth.
Manufacturing/COGS Efficiency	Gross Margin of 64.5%	This reflects supply chain optimization, favorable product mix, and the use of lower-cost inventory purchases.
Legal/Patent Defense	Successful challenge against competitor's false advertising claims	Ongoing costs are tied to defending the robust patent portfolio against infringement claims, such as those related to NMN crystallization.

The manufacturing and supply chain costs are managed to drive the gross margin, which reached 64.5% in Q3 2025, up 100 basis points from the prior year period. This efficiency is supported by a U.S.-based supply chain for Niagen ingredient manufacturing by their partner, W.R. Grace.

For G&A, the increase of $0.8 million (or 28%) over the prior year period was primarily driven by higher employee-related expenses and share-based compensation.

The S&M spend is viewed through an efficiency lens; while the absolute spend increased to support brand awareness, it improved to 25.8% of net sales, showing operating leverage.

Finance: draft 13-week cash view by Friday.

ChromaDex Corporation (CDXC) - Canvas Business Model: Revenue Streams

You're looking at the core ways ChromaDex Corporation generates cash as of late 2025. The business model clearly splits revenue between direct-to-consumer sales and business-to-business ingredient licensing and sales.

The largest component is the Tru Niagen consumer product sales. For the third quarter of 2025, this channel brought in $26 million. Honestly, the e-commerce segment within this is anchoring the growth, delivering net sales of $19 million in that same quarter, which was a 29% increase year-over-year. So, direct consumer engagement remains critical.

Next up is the Niagen ingredient sales to B2B partners. This segment generated $6.9 million in Q3 2025. This ingredient revenue is further segmented based on the end-use application, which is important for understanding the quality tiers ChromaDex services.

The third distinct revenue pathway involves Pharmaceutical-grade Niagen sales (IV/injections) to clinics. This is the newer, higher-grade vertical. For the third quarter of 2025, the sales specifically from pharmaceutical-grade Niagen were $0.5 million, which came out of the total ingredient sales. Management has been actively expanding the footprint for these prescription-based offerings, aiming to capitalize on the intravenous hydration therapy market.

Here's a quick math look at the Q3 2025 revenue composition:

Revenue Stream Component	Q3 2025 Amount (USD)
Tru Niagen Consumer Sales	$26 million
Total Niagen Ingredient Sales to B2B Partners	$6.9 million
Food-Grade Niagen Sales to Key Partners (within Ingredient Sales)	$6.4 million
Pharmaceutical-Grade Niagen Sales (IV/Injections)	$0.5 million

The overall top-line expectation for ChromaDex Corporation shows confidence in continued momentum. The full-year 2025 revenue projected to grow approximately 18% year-over-year, building on the strong performance seen in the earlier part of the year. This outlook reflects expected expansion in e-commerce, growth via established partnerships, and increased revenue from that pharmaceutical-grade Niagen ingredient business.

On the bottom line for the quarter, the company achieved a net income of $4.6 million in Q3 2025. That's a significant improvement compared to the net income of $1.9 million reported in the third quarter of 2024. The company ended the quarter with $64.3 million in cash and no debt, which definitely supports their investment strategy.

You should track the clinic count for the IV/injection business; management had previously indicated a goal to double the number of clinics offering Niagen IV by the end of 2025 from the 500 clinics reported in August 2024.

Finance: draft 13-week cash view by Friday.